Search Results

You are looking at 1 - 10 of 150 items for :

  • "thrombocytopenia" x
Clear All
Full access

Benjamin J. Miriovsky and Thomas L. Ortel

H eparin-induced thrombocytopenia (HIT) is a clinically important drug-induced complication. The rates of HIT vary significantly based on the clinical context, but estimates have ranged from 0.2% to 3%. 1 Rates are higher among general medical

Full access

Carl M. Gay, William N. William Jr, Sa A. Wang and Thein Hlaing Oo

treatment for patients with thymoma and autoimmune hematologic phenomenon T he association of pure red cell aplasia (PRCA) and aplastic anemia (AA) with thymoma is well documented. However, acquired amegakaryocytic thrombocytopenia (AAMT) is not a

Full access

Ruben A. Mesa

will also be published for polycythemia vera and essential thrombocytopenia, which will be followed by recommendations for managing atypical MPNs, said Panel Chair Ruben A. Mesa, MD, Chair, Division of Hematology and Medical Oncology, Mayo Clinic Cancer

Full access

Nikolai A. Podoltsev, Mengxin Zhu, Amer M. Zeidan, Rong Wang, Xiaoyi Wang, Amy J. Davidoff, Scott F. Huntington, Smith Giri, Steven D. Gore and Xiaomei Ma

observed between the 1,010 patients who were included in the study and the 2,464 patients who were excluded, in terms of age, sex, and race. Figure 1. Construction of the study cohort. Abbreviation: ET, essential thrombocytopenia. Among 1,010 patients, the

Full access

Robert E. Smith Jr.

Lung, breast, and colorectal cancers are the 3 most frequent causes of cancer-related death in the United States. In the past 15 years, survival has increased dramatically for patients with these tumor types, partly because improved chemotherapy caused major changes in standard care. In addition, maintaining chemotherapy dose intensity has an established a positive effect on patient outcomes. However, delivering chemotherapy at full dose and on schedule is limited primarily by myelosuppression. To determine how expert opinion about preferred chemotherapy for lung, breast, and colorectal cancers has changed over the past decade, the National Comprehensive Cancer Network (NCCN) treatment guidelines from 1996, 2000 or 2001, and 2005 for each tumor type were compared. The myelosuppressive potentials of NCCN-recommended agents were assessed using data from their prescribing information. Many agents and combinations of agents recommended in the NCCN guidelines for treating lung, breast, and colorectal cancers are associated with myelosuppression. Several of these myelosuppressive regimens, which were previously recommended for treating advanced-stage or metastatic disease, are now preferred for early-stage disease, and neoadjuvant or adjuvant therapy is now recommended in more tumor types and stages than ever before. These findings indicate that the cytotoxic agents and regimens recommended today are associated with more myelosuppression than those preferred a decade ago and are more widely used in early-stage disease when survival benefits are possible. Because of this trend toward more intensive treatment of patients with cancer, proactive steps should be taken to minimize the risk for myelosuppression and its complications while optimizing the relative dose intensity.

Full access

Sriman Swarup, Anita Sultan, Somedeb Ball, Francis Mogollon-Duffo, Nimesh Adhikari, Yin M. Myat, Myo H. Zaw, Catherine Jones and Kyaw Z. Thein

: MEDLINE, EMBASE databases, and meeting abstracts from inception through September 2018 were queried. RCTs that mention anemia, thrombocytopenia, leukopenia, neutropenia, and neutropenic fever as adverse effects were incorporated in the analysis. Mantel

Full access

Miguel Quirch, Sriman Swarup, Anita Sultan, Wai L. Thein, Zayar M. Oo, Nyein H. Yu, Myo H. Zaw, Donald P. Quick and Kyaw Z. Thein

.565–1.168; P =.261); neutropenia, 0.956 (95% CI: 0.720–1.268; P =.754); thrombocytopenia, 1.054 (95% CI: 0.450–2.470; P =.904); fatigue, 0.896 (95% CI: 0.761–1.056; P =.192); pyrexia, 1.123 (95% CI: 0.893–1.413; P =.322); and arthralgia, 1.863 (95% CI: 1

Full access

Apostolia M. Tsimberidou, Alexandra M. Adamopoulos, Yang Ye, Sarina Piha-Paul, Filip Janku, Siqing Fu, David Hong, Gerald S. Falchook, Aung Naing, Jennifer Wheler, Adoneca Fortier, Razelle Kurzrock and Kenneth R. Hess

regimens; (4) any other grade 3 nonhematologic toxicity, including symptoms/signs of vascular leak or cytokine release syndrome but excluding alopecia; (5) grade 4 thrombocytopenia; (6) any grade 4 neutropenia lasting more than 7 days (as defined by the NCI

Full access

Thanh Ho, Irbaz Bin Riaz, Maheen Akhter, Saad Ullah Malik, Anum Riaz, Muhammad Zain Farooq, Safi U. Khan, Zhen Wang, M. Hassan Murad and Andrea Wahner Hendrickson

related to myelosuppression, specifically anemia (24.7%, 15.3%–37.4%), neutropenia (10.7%, 6.6%–16.9%), and thrombocytopenia (5.0%, 1.7%–14.0%). Incidence of serious AE was 24.3% (19.4%–29.9%); dose interruption occurred in 53.3% (41.2%–65.0%) and dose

Full access

Tarek Haykal, Babikir Kheiri, Varun Samji, Yazan Zayed, Ragheed Al-Dulaimi, Inderdeep Gakhal, Areeg Bala, Jason Sotzen, Ahmed Abdalla and Ghassan Bachuwa

lipase, 6%; neutropenia, 6%; thrombocytopenia, 6%; hypophosphatemia, 5%; lymphocytopenia, 5%; anemia, 4%; and leukopenia, 3%. Conclusion: Despite s unitinib being one of the current standard treatments for patients with metastatic/advanced clear